Left ventricular hypertrophy in predialysis chronic kidney disease: Impact of cardiomuscular stress markers

Japanese Journal of Nephrology

Volumn 49, Issue 8, 2007, Pages 1007-1013

  Kimura, Tomonori ^a   Ho, Ken Ichiro ^a,b   Obi, Yoshitsugu ^a   Hayashi, Terumasa ^a  

^a Rinku General Medical Center   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Cardiomuscular biomarker; Chronic kidney disease; Human atrial natriuretic peptide; Hypoalbuminemia; Left ventricular hypertrophy

Indexed keywords

ALBUMIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; CREATININE; SERUM ALBUMIN;

ADULT; ANAMNESIS; ARTICLE; BODY FLUID; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CIRCULATION; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART STRESS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL ASSESSMENT; PREVALENCE; RENAL REPLACEMENT THERAPY; RISK FACTOR; AGED; BLOOD; CHRONIC DISEASE; CROSS-SECTIONAL STUDY; DIALYSIS; KIDNEY DISEASE; MIDDLE AGED; REGRESSION ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DIALYSIS; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; SERUM ALBUMIN;

EID: 56549094329     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003 ; 108 : 2154-2169.
2. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989 ; 36 : 286-290.
3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995 ; 47 : 186-192.
4. Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Hand J, King A, Barre PE. The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 1990 ; 55 : 114-120.
5. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population : identifying opportunities for intervention. Am J Kidney Dis 1996 ; 27 : 347-354.
6. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005 ; 46 : 320-327.
7. Cockroft D GM. Prediction of creatinine clearance from serum creatinine. Nephron 1976 ; 16 : 31-41.
8. Devereux RB, Pickering TG, Alderman MH, Chien S, Borer JS, Laragh JH. Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension 1987 ; 9 : II 53-60.
9. McMahon LP, Roger SD, Levin A. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 2004 ; 15 : 1640-1647.
10. Dietz JR. Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res 2005 ; 68 : 8-17.
11. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction : the Framingham heart study. JAMA 2002 ; 288 : 1252-1259.
12. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000 ; 35 : 250-256.
13. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease : impact of decline in hemoglobin. Am J Kidney Dis 1999 ; 34 : 125-134.
14. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005 ; 293 : 90-95.
15. Miki T, Miura T, Yano T, Takahashi A, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Nishihara M, Naitoh K, Ohori K, Shimamoto K. Alteration in erythropoietin induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther 2006 ; 317 : 68-75.
16. Iseki K, Miyasato F, Tokuyama K, Nishime K, Uehara H, Shiohira Y, Sunagawa H, Yoshihara K, Yoshi S, Toma S, Kowatari T, Wake T, Oura T, Fukiyama K. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int 1997 ; 51 : 1212-1217.
17. Moon KH, Song IS, Yang WS, Shin YT, Kim SB, Song JK, Park JS. Hypoalbuminemia as a risk factor for progressive left-ventricular hypertrophy in hemodialysis patients. Am J Nephrol 2000 ; 20 : 396-401.
18. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001 ; 103 : 1869-1874.
19. Bakris GL, Tarka EA, Waterhouse B, Goulding MR, Madan A, Anderson KM. Cardiovascular risk factors in hypertension : rationale and design of studies to investigate the effects of controlled-release Carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol 2006 ; 98 : 46-52.